SG11202001211TA - Tim-3 antagonists for the treatment and diagnosis of cancers - Google Patents

Tim-3 antagonists for the treatment and diagnosis of cancers

Info

Publication number
SG11202001211TA
SG11202001211TA SG11202001211TA SG11202001211TA SG11202001211TA SG 11202001211T A SG11202001211T A SG 11202001211TA SG 11202001211T A SG11202001211T A SG 11202001211TA SG 11202001211T A SG11202001211T A SG 11202001211TA SG 11202001211T A SG11202001211T A SG 11202001211TA
Authority
SG
Singapore
Prior art keywords
tim
cancers
antagonists
diagnosis
treatment
Prior art date
Application number
SG11202001211TA
Inventor
Anke Klippel
Laurence Celine Menard
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202001211TA publication Critical patent/SG11202001211TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202001211TA 2017-08-28 2018-08-28 Tim-3 antagonists for the treatment and diagnosis of cancers SG11202001211TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551137P 2017-08-28 2017-08-28
PCT/US2018/048375 WO2019046321A1 (en) 2017-08-28 2018-08-28 Tim-3 antagonists for the treatment and diagnosis of cancers

Publications (1)

Publication Number Publication Date
SG11202001211TA true SG11202001211TA (en) 2020-03-30

Family

ID=63678676

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001211TA SG11202001211TA (en) 2017-08-28 2018-08-28 Tim-3 antagonists for the treatment and diagnosis of cancers

Country Status (13)

Country Link
US (2) US11787859B2 (en)
EP (1) EP3676616A1 (en)
JP (1) JP2020531854A (en)
KR (1) KR20200044899A (en)
CN (1) CN111094982A (en)
AU (1) AU2018323462A1 (en)
BR (1) BR112020003362A2 (en)
CA (1) CA3078605A1 (en)
EA (1) EA202090634A1 (en)
IL (2) IL310079A (en)
MX (1) MX2020001980A (en)
SG (1) SG11202001211TA (en)
WO (1) WO2019046321A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118634A1 (en) * 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
UY37325A (en) * 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware MONOCLONAL ANTIBODIES THAT LINK TO TIM3 TO STIMULATE IMMUNE RESPONSES AND COMPOSITIONS CONTAINING THEM
EP3658914A1 (en) * 2017-07-28 2020-06-03 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
SG11202001211TA (en) 2017-08-28 2020-03-30 Bristol Myers Squibb Co Tim-3 antagonists for the treatment and diagnosis of cancers
CN113164601B (en) * 2019-09-19 2023-09-29 上药生物治疗（香港）有限公司 Isolated antigen binding proteins and uses thereof
CN113214396B (en) * 2020-07-31 2022-04-19 北京市神经外科研究所 Single-chain antibody of anti-TIM 3 and application thereof in preparing medicine for treating tumor
WO2022165511A1 (en) * 2021-01-29 2022-08-04 Lapix Therapeutics, Inc. Tartaric acid analogs and uses thereof
WO2023019244A1 (en) 2021-08-13 2023-02-16 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383456C (en) 1999-08-23 2016-06-07 Clive Wood Pd-1, a receptor for b7-4, and uses therefor
CN1753912B (en) 2002-12-23 2011-11-02 惠氏公司 Antibodies against PD-1 and uses therefor
RU2406760C3 (en) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
CA3018525C (en) 2005-07-01 2023-08-01 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
BRPI0812913B8 (en) 2007-06-18 2021-05-25 Merck Sharp & Dohme monoclonal antibodies or antibody fragment to human programmed death receptor pd-1, polynucleotide, method of producing said antibodies or antibody fragments, composition comprising them and use thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8114845B2 (en) 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
PL3279215T3 (en) 2009-11-24 2020-06-29 Medimmune Limited Targeted binding agents against b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
ES2682078T3 (en) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anti-TIM-3 antibody
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN103987405B (en) 2011-11-28 2017-03-29 默克专利股份公司 Anti- PD L1 antibody and application thereof
EA037351B8 (en) * 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Method of treating cancer using an anti-pd-1 and anti-ctla-4 antibody combination
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
JP6623353B2 (en) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー Anti-PD-1 antibodies and their use for therapy and diagnosis
CN104072615B (en) 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 A kind of people's Tim-3 fusion protein that can block Tim-3 signal path
JOP20200096A1 (en) * 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CN114107424A (en) * 2014-10-08 2022-03-01 诺华股份有限公司 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
KR20170075778A (en) 2014-10-27 2017-07-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Anti-tim-3 antibodies
MX2017005258A (en) 2014-10-31 2017-07-26 Oncomed Pharm Inc Combination therapy for treatment of disease.
TWI618717B (en) 2014-11-06 2018-03-21 赫孚孟拉羅股份公司 Anti-tim3 antibodies and methods of use
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN104592388B (en) 2015-03-02 2017-05-31 中国人民解放军总医院 A kind of antigen-binding portion thereof of the monoclonal antibody of anti-human Tim 3
WO2016144803A2 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
WO2016186177A1 (en) * 2015-05-20 2016-11-24 大日本住友製薬株式会社 Combination of wt1 antigen peptide and immunomodulator
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN108139394B (en) 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 Cell-based FRET assay for determining simultaneous binding
CA2992853A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
CA3004117A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017118634A1 (en) * 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
MA44659B1 (en) 2016-04-12 2021-12-31 Symphogen As ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
KR102543118B1 (en) 2016-05-27 2023-06-14 아게누스 인코포레이티드 Anti-tim-3 antibodies and methods of use thereof
UY37325A (en) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware MONOCLONAL ANTIBODIES THAT LINK TO TIM3 TO STIMULATE IMMUNE RESPONSES AND COMPOSITIONS CONTAINING THEM
CN106632675A (en) 2016-12-15 2017-05-10 常州格露康生物医药科技有限公司 Anti-human Tim-3 monoclonal antibody 8E11 and preparation method thereof
SG11202001211TA (en) 2017-08-28 2020-03-30 Bristol Myers Squibb Co Tim-3 antagonists for the treatment and diagnosis of cancers

Also Published As

Publication number Publication date
KR20200044899A (en) 2020-04-29
CN111094982A (en) 2020-05-01
CA3078605A1 (en) 2019-03-07
EP3676616A1 (en) 2020-07-08
US20210171629A1 (en) 2021-06-10
WO2019046321A1 (en) 2019-03-07
JP2020531854A (en) 2020-11-05
MX2020001980A (en) 2020-03-24
BR112020003362A2 (en) 2020-08-18
US11787859B2 (en) 2023-10-17
IL310079A (en) 2024-03-01
EA202090634A1 (en) 2020-06-17
IL272821A (en) 2020-04-30
US20240117044A1 (en) 2024-04-11
AU2018323462A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
IL272821A (en) Tim-3 antagonists for the treatment and diagnosis of cancers
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL271230A (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL274246A (en) Diagnostic and therapeutic methods for cancer
SG10202006688RA (en) Bicyclic compounds for diagnosis and therapy
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL248836A0 (en) Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
IL273071A (en) Diagnostic and therapeutic methods for cancer
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
IL281274A (en) Treatment of diuretic resistance
EP3494877C0 (en) Device for the examination of neurons
GB201413357D0 (en) Antibodies for treatment and diagnosis
IL250507A0 (en) Anti-ck8 antibodies for use in the treatment of cancers
GB201715194D0 (en) Compounds and their therapeutic use
IL265889A (en) Ligands of the fsh hormone receptor in the diagnosis and treatment of tumors
IL270011B (en) Therapeutic compounds and methods
GB201709840D0 (en) Methods and medical uses
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
HUE058652T2 (en) Compounds and their use in the treatment of schistosomiasis
IL272147A (en) Methods and compositions for the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201500875D0 (en) Antibodies for treatment and diagnosis
GB201713284D0 (en) Therapy and diagnostics
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism